Patent · US Active

MTH1 inhibitors for treatment of inflammatory and autoimmune conditions

US10632125B2 · kind B2 · utility

1Cited by

3References

23Claims

0Family size

Assignee

THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING · SE

Inventors

Martin Scobie · Uppsala, SE
Olov Wallner · Solna, SE
Tobias Koolmeister · Stockholm, SE
Karl Sven Axel Vallin · Stockholm, SE
Carl Martin Henriksson · Bromma, SE
Evert Homan · Sollentuna, SE
Thomas Helleday · Stockholm, SE
Sylvain Jacques · Val-de-Reuil, FR
Roland Julius Yu Fiskesund · Kramfors, SE

Key dates

Filing date	Aug 31, 2018
Grant date	Apr 28, 2020
Priority date	—
Expiry date	Aug 31, 2038

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.